Literature DB >> 1156505

Further analysis of the anti-tumour effect in vitro of peritoneal exudate cells from mice treated with Corynebacterium parvum.

A Ghaffar, R T Cullen, M A Woodruff.   

Abstract

Administration of C. parvum to both intact and thymectomized mice resulted in the appearance in the peritoneal exudate of cells which inhibited tumour growth in vitro. This effect was mediated by intact, viable adherent cells, which it seems reasonable to categorize as macrophages, and was contingent on contact between the effector and target cells. No co-operation was observed between lymph node cells from C. parvum treated mice and peritoneal exudate cells from normal mice.

Entities:  

Mesh:

Year:  1975        PMID: 1156505      PMCID: PMC2009347          DOI: 10.1038/bjc.1975.3

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  11 in total

1.  Tumour resistance of mice infected with salmonella enteritidis 11RX. The role of peritoneal exudate cells.

Authors:  M P Ashley; D Hardy
Journal:  Aust J Exp Biol Med Sci       Date:  1973-12

2.  Tumour growth and non-specific immunity in rats: the mechanisms involved in inhibition of tumour growth.

Authors:  R Keller; M W Hess
Journal:  Br J Exp Pathol       Date:  1972-10

3.  Mechanism of immunologically specific killing of tumour cells by macrophages.

Authors:  R Evans; P Alexander
Journal:  Nature       Date:  1972-03-24       Impact factor: 49.962

4.  Mechanisms by which activated normal macrophages destroy syngeneic rat tumour cells in vitro. Cytokinetics, non-involvement of T lymphocytes, and effect of metabolic inhibitors.

Authors:  R Keller
Journal:  Immunology       Date:  1974-08       Impact factor: 7.397

5.  Possible role of macrophage mediated nonspecific cytotoxicity in tumour resistance.

Authors:  J B Hibbs; L H Lambert; J S Remington
Journal:  Nat New Biol       Date:  1972-01-12

6.  In vitro inhibition of tumour cell growth and DNA synthesis by peritoneal and lung macrophages from mice injected with Corynebacterium parvum.

Authors:  M Olivotto; R Bomford
Journal:  Int J Cancer       Date:  1974-04-15       Impact factor: 7.396

7.  Immunologically specific activation of macrophages armed with the specific macrophage arming factor (SMAF).

Authors:  R Evans; H Cox; P Alexander
Journal:  Proc Soc Exp Biol Med       Date:  1973-05

8.  Thymus-derived lymphocytes produce an immunologically specific macrophage-arming factor.

Authors:  R Evans; C K Grant; H Cox; K Steele; P Alexander
Journal:  J Exp Med       Date:  1972-11-01       Impact factor: 14.307

9.  Cytostatic elimination of syngeneic rat tumor cells in vitro by nonspecifically activated macrophages.

Authors:  R Keller
Journal:  J Exp Med       Date:  1973-09-01       Impact factor: 14.307

10.  Anti-tumour effect in vitro of lymphocytes and macrophages from mice treated with Corynebacterium parvum.

Authors:  A Ghaffar; R T Cullen; N Dunbar; M F Woodruff
Journal:  Br J Cancer       Date:  1974-03       Impact factor: 7.640

View more
  15 in total

1.  The role of macrophages in the adjuvant effect on antibody production of Corynebacterium parvum.

Authors:  S R Watson; V S Sljivić
Journal:  Clin Exp Immunol       Date:  1976-01       Impact factor: 4.330

2.  Induction of enhanced resistance against encephalomyocarditis virus infection of mice by nonviable Mycobacterium tuberculosis: mechanisms of protection.

Authors:  D L Lodmell; L C Ewalt
Journal:  Infect Immun       Date:  1978-12       Impact factor: 3.441

3.  The in vivo cytostatic effect induced by Propionibacterium granulosum on murine tumor cells.

Authors:  P Janik; W Roszkowski; H L Ko; S Szmigielski; G Pulverer; J Jeljaszewicz
Journal:  J Cancer Res Clin Oncol       Date:  1980       Impact factor: 4.553

4.  Levamisole augments the cytotoxic T-cell response depending on the dose of drugs and antigen administered.

Authors:  R B Faanes; P Dillon; Y S Choi
Journal:  Clin Exp Immunol       Date:  1977-03       Impact factor: 4.330

5.  The adjuvant effect of Corynebacterium parvum: T-cell dependence of macrophage activation.

Authors:  V S Sljivić; S R Watson
Journal:  J Exp Med       Date:  1977-01-01       Impact factor: 14.307

6.  Complement activation in vivo in cancer patients receiving C. parvum immunotherapy.

Authors:  H Biran; J L Moake; R C Reed; J U Gutterman; E M Hersh; E J Freireich; G M Mavligit
Journal:  Br J Cancer       Date:  1976-11       Impact factor: 7.640

7.  Radiolabelling of Corynebacterium parvum and its distribution in mice.

Authors:  T E Sadler; W A Cramp; J E Castro
Journal:  Br J Cancer       Date:  1977-03       Impact factor: 7.640

8.  Lack of correlation between in vivo rejection of syngeneic fibrosarcomas and in vitro non-specific macrophage cytotoxicity.

Authors:  R Evans; C G Booth; F Spencer
Journal:  Br J Cancer       Date:  1978-11       Impact factor: 7.640

9.  Immunological mechanisms in metastatic spread and the antimetastatic effects of C. parvum.

Authors:  P D Jones; J E Castro
Journal:  Br J Cancer       Date:  1977-05       Impact factor: 7.640

10.  The effect of Corynebacterium parvum therapy on immunoglobulin class and IgG subclass levels in cancer patients.

Authors:  K James; G J Clunie; M F Woodruff; W H McBride; W H Stimson; R Drew; D Catty
Journal:  Br J Cancer       Date:  1975-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.